Identification of a 2,4-diaminopyrimidine scaffold targeting Trypanosoma brucei pteridine reductase 1 from the LIBRA compound library screening campaign.
A549 Cells
Antimetabolites, Antineoplastic
/ pharmacology
Antineoplastic Agents
/ chemistry
Cell Proliferation
Drug Synergism
Enzyme Inhibitors
/ chemistry
High-Throughput Screening Assays
/ methods
Humans
Macrophages
/ drug effects
Methotrexate
/ pharmacology
Models, Molecular
Molecular Structure
Oxidoreductases
/ antagonists & inhibitors
Pyrimidines
/ chemistry
Structure-Activity Relationship
Trypanosoma brucei brucei
/ enzymology
Anti-parasitic drug discovery
High throughput screening
LIBRA compound library
Pteridine reductase 1
Journal
European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510
Informations de publication
Date de publication:
01 Mar 2020
01 Mar 2020
Historique:
received:
23
08
2019
revised:
31
12
2019
accepted:
06
01
2020
pubmed:
27
1
2020
medline:
31
10
2020
entrez:
27
1
2020
Statut:
ppublish
Résumé
The LIBRA compound library is a collection of 522 non-commercial molecules contributed by various Italian academic laboratories. These compounds have been designed and synthesized during different medicinal chemistry programs and are hosted by the Italian Institute of Technology. We report the screening of the LIBRA compound library against Trypanosoma brucei and Leishmania major pteridine reductase 1, TbPTR1 and LmPTR1. Nine compounds were active against parasitic PTR1 and were selected for cell-based parasite screening, as single agents and in combination with methotrexate (MTX). The most interesting TbPTR1 inhibitor identified was 4-(benzyloxy)pyrimidine-2,6-diamine (LIB_66). Subsequently, six new LIB_66 derivatives were synthesized to explore its Structure-Activity-Relationship (SAR) and absorption, distribution, metabolism, excretion and toxicity (ADMET) properties. The results indicate that PTR1 has a preference to bind inhibitors, which resemble its biopterin/folic acid substrates, such as the 2,4-diaminopyrimidine derivatives.
Identifiants
pubmed: 31982652
pii: S0223-5234(20)30014-3
doi: 10.1016/j.ejmech.2020.112047
pii:
doi:
Substances chimiques
Antimetabolites, Antineoplastic
0
Antineoplastic Agents
0
Enzyme Inhibitors
0
Pyrimidines
0
2,4-diaminopyrimidine
156-81-0
Oxidoreductases
EC 1.-
pteridine reductase
EC 1.1.1.33
Methotrexate
YL5FZ2Y5U1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
112047Informations de copyright
Copyright © 2020 Elsevier Masson SAS. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.